For patients with Type 1 diabetes who need a kidney transplant, simultaneous pancreas-kidney (SPK) transplantation offers a higher survival rate than other options but with some increased risks, reports a study.
Alexander Wiseman, MD (University of Colorado) stated that, “This study helps patients with Type 1 diabetes and their providers decide upon the best transplant treatment option.”
The study included nearly 6,900 Type 1 diabetics undergoing SPK transplantation. When SPK transplant was successful with both organs functional at one year, the long-term survival rate was 89 percent, compared to 80 percent for patients receiving a kidney from a living donor and 65 percent for those receiving a kidney (but not pancreas) from a deceased donor (All SPK transplants came from deceased donors.). However, SPK recipients were about two percent more likely to die during the first year after transplantation. There was also a ten to fifteen percent chance that the transplanted pancreas would fail during the first year. When this happened, the long-term survival rate dropped to 74 percent.
Patients with Type 1 diabetes and advanced kidney disease face a difficult decision, according to Wiseman: “Should they try to get on the waiting list for SPK and assume the greater surgical risk, or should they accept a kidney from a living donor and live with continued diabetes?” If they opt for kidney transplant alone, they then must decide whether to undergo a separate pancreas transplant later on. In Wiseman’s study, even this option did not lead to better survival than successful SPK transplantation.
The new findings help to guide this decision by comparing the benefits and risks of the various transplant options. “Overall, the chances for better long-term success favor the SPK option, particularly if the waiting time for an SPK is not long – this varies with regions of the United States.”
The study is limited by a lack of information on why the SPK recipients lived longer. One theory is that improved diabetes control helps avoid cardiovascular disease. In addition, although the study provides important new evidence that the survival rate is higher after successful SPK transplantation, it does not help in predicting which patients will have a successful SPK transplant.
Advance in release for the Clinical Journal of the American Society of Nephrology (CJASN).
Do you have patients in pain?
Nearly 6,000 Anodyne Therapy Care Providers in 35 countries worldwide are helping thousands of patients per month with painful, circulatory problems get relief.
“The Anodyne Therapy has improved the quality of my life beyond description. I can’t thank you enough.” C.C. Pomona, KS
To learn how you can help your patients get back to life, click here.